Adverse events ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events (number) · people with acute pancreatitis
1 finding from 1 review
Adverse events Any adverse event · participants with chronic prostatitis/chronic pelvic pain syndrome
Alpha blockers may leads to higher adverse events Any adverse event compared with placebo (low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether higher‐dose heparin changes adverse events (thrombocytopenia) compared with standard‐dose heparin (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Intervention not reported
Serious adverse events (proportion) · people with acute pancreatitis
It is very uncertain whether the intervention changes serious adverse events (proportion) (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinically important adverse events · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ treatment emergent · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Tchivileva et al 2010: at least one treatment-emergent adverse event was reported by five participants (12.5%) during the propranolol period (nausea, diarrhoea, insomnia, dizziness, fatigue) and four participants (10%)…
1 study · 40 participants
GRADE not reported
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
1 finding from 1 review